<SEC-DOCUMENT>0000950170-23-029354.txt : 20230622
<SEC-HEADER>0000950170-23-029354.hdr.sgml : 20230622
<ACCEPTANCE-DATETIME>20230622142258
ACCESSION NUMBER:		0000950170-23-029354
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230622
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230622
DATE AS OF CHANGE:		20230622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarepta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000873303
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				930797222
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14895
		FILM NUMBER:		231032927

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 415
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-274-4000

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 415
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sarepta Therapuetics, Inc.
		DATE OF NAME CHANGE:	20120712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVI BIOPHARMA INC
		DATE OF NAME CHANGE:	19980930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIVIRALS INC
		DATE OF NAME CHANGE:	19970123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>srpt-20230622.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-06-22T14:19:21.5235+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srpt="http://www.sarepta.com/20230622" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4dbbefb2-f8ef-4307-90b2-ec771fd7645c" name="dei:EntityCentralIndexKey" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37">0000873303</ix:nonNumeric><ix:nonNumeric id="F_6a49b71e-b558-431a-b87f-853cab1f495b" name="dei:AmendmentFlag" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="srpt-20230622.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_429bdaee-dff8-43d5-a577-a638882dff37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000873303</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-22</xbrli:startDate><xbrli:endDate>2023-06-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8d7bd87-fd66-4544-9fa7-04a4e249a9e5" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0c2c589-f5bc-4254-b355-76250900c9d3" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 22, 2023</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fde24faf-9d45-4dab-a1a5-200f99e026e1" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarepta Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_099970a2-9f04-4156-8107-643658091716" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e1dd7bf-5fba-4aa7-b944-48f1f7aeea01" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-14895</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ff0f1906-fb4f-4d54-85af-e0a817649a6c" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93-0797222</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79e063fa-abcd-4efe-900d-c3a5c3d82391" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215 First Street</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84c6b6de-054b-4d6d-b0fa-30f13206ac83" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f7965db1-ec66-4709-a25b-5669ac9e7745" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eaa93eb6-3670-4512-b412-71c527eaf3da" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02142</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f7542612-a453-4dd2-ba90-667321b4e6df" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9012b0c5-2e64-4f73-8127-e2c175ae99ed" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">274-4000</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44335470-b4cd-4f90-9c36-3521605c8d4f" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4580c544-7a2e-4292-8a62-005db3c62943" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39e27626-dece-41ed-813a-c266e96a7c44" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18165d19-5768-4a87-b9d5-f1998d3916a6" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8addc01f-e281-487a-aa99-10965b717b7b" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b14555e-291d-4bd7-afca-26a552180715" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SRPT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9a23eab1-c5b7-4625-bea2-3f1d9f72c57f" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_4fe20c0a-141f-4c8a-bd18-ff47e813a508" contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 22, 2023, Sarepta Therapeutics, Inc. (the &#x201c;Company&#x201d;) announced that the U.S. Food and Drug Administration granted accelerated approval for ELEVIDYS (delandistrogene moxeparvovec-rokl), the Company&#x2019;s gene therapy product for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (&#x201c;DMD&#x201d;) with a confirmed mutation in the DMD gene. A copy of the Company&#x2019;s press release is attached as Exhibit 99.1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The information in this report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 and shall not be deemed &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01. Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"></td>
    <td style="width:2.02%;"></td>
    <td style="width:90.9%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="srpt-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press Release dated June 22, 2023: Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarepta Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: June 22, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Douglas S. Ingram</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Douglas S. Ingram</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>srpt-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(102,27,98,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><img src="img45281506_0.jpg" alt="img45281506_0.jpg" style="width:624px;height:75px;"></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,27,98,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(102,27,98,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:line-through;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">ELEVIDYS (delandistrogene moxeparvovec-rokl) is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne based on expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">  </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:line-through;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">ELEVIDYS is a one-time treatment designed to treat the underlying genetic cause of Duchenne</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:line-through;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Sarepta will host a conference call on June 22 at 4:30 p.m. ET</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CAMBRIDGE, Mass., June 22, 2023 (BUSINESS WIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric  patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">DMD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> gene. This indication is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">DMD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> gene.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230622454844/en/</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img45281506_1.jpg" alt="img45281506_1.jpg" style="width:154px;height:101px;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ELEVIDYS addresses the root genetic cause of Duchenne &#x2013; mutations in the dystrophin gene that result in the lack of dystrophin protein &#x2013; by delivering a gene that codes for a shortened form of dystrophin</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">to muscle cells known as ELEVIDYS micro-dystrophin. This accelerated approval is based on an increase in ELEVIDYS micro-dystrophin protein expression in skeletal muscle. ELEVIDYS is supported by biologic and empirical evidence, in addition to efficacy data from two clinical studies: SRP-9001-102 and SRP-9001-103 and safety data from SRP-9001-101, SRP-9001-102 and SRP-9001-103. Acute serious liver injury, immune-mediated myositis and myocarditis have occurred in patients treated with ELEVIDYS. The most common adverse reactions in clinical studies were vomiting, nausea, liver function test increased, pyrexia and thrombocytopenia.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Consistent with the accelerated approval pathway, the company has committed to the completion of a confirmatory trial. EMBARK, the global, randomized, double-blind, placebo-controlled Phase 3 trial for ELEVIDYS, will serve as the post-marketing confirmatory trial and is fully enrolled with top-line results expected in late 2023.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Duchenne is a relentlessly progressive, degenerative disease, robbing children of muscle function</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;vertical-align:super;font-size:7.37pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">[i]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">,&#x201d; said Jerry Mendell, M.D., pediatric neurologist and principal investigator in the Center for Gene Therapy at Nationwide Children&#x2019;s Hospital. &#x201c;The increases in ELEVIDYS dystrophin expression and the functional results that we see can make a difference in the lives of our patients.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;The approval of ELEVIDYS is a watershed moment for the treatment of Duchenne. ELEVIDYS is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,&#x201d; said Doug Ingram, president and chief executive officer, Sarepta. &#x201c;As we prepare to launch ELEVIDYS, we should acknowledge and celebrate the decades of dedication and work from the patient community, families, clinicians, and our Sarepta colleagues that resulted in today&#x2019;s approval. Our confirmatory trial, EMBARK, should read out in the fourth quarter of this year. If EMBARK confirms the benefits seen in our prior trials, Sarepta will move rapidly to submit a BLA supplement to expand the approved label as broadly as good science permits.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Today&#x2019;s decision marks an important moment in gene therapy for patients living with Duchenne,&#x201d; said Pat Furlong, founding president and chief executive officer, Parent Project Muscular Dystrophy. &#x201c;It&#x2019;s been the lifelong work of so many in the Duchenne community. Our work continues until all patients in our community have access to therapy.&#34;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Patients and physicians can access more information at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">www.SareptAssist.com</font><font style="background-color:rgba(0,0,0,0);color:rgba(91,155,213,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">or by calling 1-888-727-3782.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Conference call details</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">At 4:30 p.m. June 22, 2023, Sarepta will host a conference call and webcast to discuss this update.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The event will be webcast live under the investor relations section of Sarepta&#x2019;s website at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">https://investorrelations.sarepta.com/events-presentations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">this online form</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">About ELEVIDYS (delandistrogene moxeparvovec-rokl)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose gene transfer therapy for intravenous infusion designed to address the underlying cause of Duchenne muscular dystrophy through the targeted</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS has been evaluated in three on-going clinical studies: SRP-9001-101, SRP-9001-102 and SRP-9001-103. Accelerated approval was primarily based on data from SRP-9001-102 and SRP-9001-103. More than 80 treated patients across the three studies contributed to the safety profile of ELEVIDYS. ELEVIDYS is also being studied in Study SRP-9001-301 (also known as EMBARK), a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial in 126 participants with Duchenne between the ages of 4 to 7 years.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">IMPORTANT SAFETY INFORMATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CONTRAINDICATION:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">DMD </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">gene.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">WARNINGS AND PRECAUTIONS:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Acute Serious Liver Injury</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Acute serious liver injury has been observed with ELEVIDYS. Administration of ELEVIDYS may result in elevations of liver enzymes (e.g., GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks.  </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT and total bilirubin levels return to near baseline levels).  </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, a consultation with a specialist is recommended.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Immune-mediated Myositis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">DMD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> gene.  Symptoms of severe muscle weakness including dysphagia, dyspnea and hypophonia were observed.  </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Limited data are available for ELEVIDYS treatment in patients with mutations in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">DMD </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">gene between exons 1 to 17 and exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea or hypophonia as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient&#x2019;s clinical presentation and medical history if these symptoms occur.     </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Myocarditis:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Advise patients to contact a physician immediately if they experience cardiac symptoms.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pre-existing Immunity against AAVrh74:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all subjects developed anti-AAVrh74 antibodies. </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Perform baseline testing for the presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Adverse Reactions:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The most common adverse reactions (incidence &#x2265; 5%) reported in clinical studies were vomiting, nausea, liver function test increased, pyrexia, and thrombocytopenia.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Sarepta is responsible for global development and manufacturing for ELEVIDYS, and distribution within the U.S. will commence immediately. In December 2019, Sarepta partnered with Roche to accelerate access to ELEVIDYS for patients outside the United States.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ELEVIDYS is approved under accelerated review based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication in this and other age groups will be contingent upon verification of a clinical benefit in confirmatory trials. ELEVIDYS has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For further information, please see the full </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prescribing Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">About Sarepta Therapeutics</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">www.sarepta.com</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> or follow us on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Twitter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">LinkedIn</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Instagram</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Facebook</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Internet Posting of Information</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We routinely post information that may be important to investors in the 'For Investors' section of our website at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.sarepta.com</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">. We encourage investors and potential investors to consult our website regularly for important information about us.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">This press release contains &#x201c;forward-looking statements.&#x201d; Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as &#x201c;believe,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;plan,&#x201d; &#x201c;expect,&#x201d; &#x201c;will,&#x201d; &#x201c;may,&#x201d; &#x201c;intend,&#x201d; &#x201c;prepare,&#x201d; &#x201c;look,&#x201d; &#x201c;potential,&#x201d; &#x201c;possible&#x201d; and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, business plans, priorities, research and development programs; ELEVIDYS&#x2019; continued approval potentially being contingent upon verification and description of clinical benefit in confirmatory trial(s); the potential for ELEVIDYS to bring us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of degenerative disease; the potential benefits and risks of ELEVIDYS; and expected plans and milestones, including our expectation of EMBARK serving as the post-marketing confirmatory trial, rapidly moving to submit a BLA supplement to expand the approved label as broadly as good science permits if EMBARK confirms the benefits seen in prior trials, and receiving top-line results from EMBARK in late 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the FDA may not approve a supplement to expand the approved label for ELEVIDYS; continued approval may be contingent upon verification of a clinical benefit in confirmatory trials; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business, as well as the development of our product candidates and our financial and contractual obligations; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and to secure in a timely manner manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data may not be sufficient for obtaining regulatory approval; we are subject to uncertainty related to reimbursement policies; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials of our product candidates are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading &#x201c;Risk Factors&#x201d; in our most recent Annual Report on Form 10-K for the year ended December 31, 2022, and Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Any of the foregoing risks could materially and adversely affect the Company&#x2019;s business, results of operations and the trading price of Sarepta&#x2019;s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investor Contact:</font><font style="color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ian Estepan, 617-274-4052</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">iestepan@sarepta.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Media Contact:</font><font style="color:rgba(23,42,132,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Tracy Sorrentino, 617-301-8566</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">tsorrentino@sarepta.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Source: Sarepta Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[i]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Duan D, et al. Nat Rev Dis Primers. 2021;7(1):13.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img45281506_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45281506_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C S # 2(  A$! Q$!_\0
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M*3=BX1N[$D%JTF,"K8TYS_":ZC0M">\QM7-=2OA!\=*Y)UTG8]"&'5M3R_\
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M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ59HHNP*QM156XM]HZ5IU5NV&WK33=Q-&+(,&HZFEZU#WK='-+<44[%(M.H
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M***]0\4**** "BBB@ HHHH **** "K6F7266HPSR*6B!VR*.I0C#?H356D/
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MCHHHJC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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..HHHH 1NE5WHHIHEG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img45281506_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45281506_1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M  #VU@ !     -,M2% @(
M                        $6-P<G0   %0    ,V1E<V,   &$    ;'=T
M<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M%&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M  0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E
M>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M$G-21T(@245#-C$Y-C8M,BXQ
M                              !865H@        \U$  0    $6S%A9
M6B                      6%E:(        &^B   X]0   Y!865H@
M    8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6
M245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W
M=W<N:65C+F-H
M             &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M              !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M   !6%E:(       3 E6 %    !7'^=M96%S          $
M           "CP    )S:6<@     $-25"!C=7)V        !      %  H
M#P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\
M ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L
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MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 3T!X ,!$0 "$0$#$0'_Q  ?  $
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M%[!8E^K>X<_XT_'S_2]1?VUG(?Y+>$K_ '!TP_Z=Q7_*K\??[!/E?#?GM/\
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M %SF2 +D@+CNEH)T;Q@ $GV([("Y\-A\RT!3.$A5,4'"(J"<P 4%TQ4$1'X
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M8F /3L;\Q3#_ $@';-8ESI<@(#W[=_3[93!_-W ._P";"+G")A%P(@'Q[_F
M1_J <?QVHN , CV[&_.4P!_.(=@_..$7ZPB_FJLDB11550B2213'544,4B:9
M"%\1C**&$")E*7Y0F.8H 'J(]LEK7.<&M!<YQ :UH)<238  9DDY #:<E!(
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M(F$3")A$PB81:X7T1A_%1QD_*C=_T'2S=+N,?P@T[_,.%_XF5UAPG?ZEA/\
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M<#UW6Y+TO.I-'<X:;,5*],(JK[_UW'LWELB8GQH05SK;A4K)M?:JS<++NF*
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MYXC42N9+"'!LS',+RU_\T7$7!(<&D;+KZ&\7),)B.82T6[0?QLFS:R$>^;*
MJW>,'J";IF[05#T41<MEDETCAZ'(H4P?'/'6>&6GFFIYXWQ3P2OAFB>W5?%+
M$\LDC>W\5S'M<UPV@BQ 6RK'->QKV.#F.:',<#<.:X M<#O#@0;^A>=F)65&
M'79Y06#2W'JD:KH5KFZI>-UW$PNY2LS+V#G&6OJ(DA*6,&\C%.&LDQ3F9U_6
M(18Z#A 73!>3:B8R1E2YM3W*6@M'I-ICBN/XOA]+B&%:,8:!'!74L552RXQB
MSGT]'KPSLD@E=34L5?5-#V/U)6026!#2N <(.+24&&T]'3S20U%?/[Y\3W1R
M-IJ<!\H#F$.;QDCHF7!%VEXS%UKO]/"-W)O/F;HK7\5M':S%J^NS2T7.0BMC
MW5B[)2*2![;:@7>(SA3 E*-8PD&/G^8FLXF44SD.94"FW'X8Y]&]%>#32S%Z
MC M'Y9(\+?089#48+ADT9Q7$RW#L/+(G4OA023FK][JN;'3/(+0TKK31EM=B
M&.4%.VLK&@SMFG<RJG8X4\%YIO?"06#@P1Y@B[QDMZW:FRZMIK6EZVO=W#QK
M4M>56;N-C6CV2LD_)$P3):0>%9,41*H\>'32%)JW*8@*KG3*91,@F4+Y38!@
M=?I+C>$Z/X6R.3$<9Q"EPVB;-*V&(U%7*V&,RRNN(XVN<'/?9Q:T$AKC9IV!
MJZJ&AI*BLG+A#30R3REK==P9&TN.JT6+C86:T;387&U:>/+3K>\H=U2,M"Z/
M?N..FM2F<)1X5T[-[M.7:I^+RG<[=%D7", X6 H*C&4QNR%B)Q;FL$J)/:3>
MC_!YW+F@FC$--4Z4Q,TSQRS'3>S6RQ8#3O-M:*EPQKF.JVM)(X_$WR"35UA1
MP7U%TGC&GV+5[WLH"<,IKEK>+U75;VW-G23D'BR<B60-;JG+C7[5MC\1)J8L
MG%;C=8;#*R,[/SNBM4S$W-R[Q>0E9>6D:1"NY"3DG[HZKEZ_?.E57+MVX447
M<+J'55.8YA$?/OA$I::AT_TVHZ.GAI*2ETKT@IZ:EIHV0T]/3PXK51PP00L
M9%#%&UK(XV ,8T!K0 %W%@KWRX/A4DKW2228=1ODD>XN>][Z>-SG/<<W.<22
M2<R3<YKLG('>=$XV:>O>ZMD/E&=4HD*K*.TFQ2*24L^5439PU?AFZAB%<S5@
MEG#.(BD#&(F=X[3.NHDV3653_#HAHKBVFVDF$Z,8)$),0Q:J;!&YY(AIXFM,
MM35U+P"8Z:DIF25%0\ N$4;M0.>6M.7$L0I\*HJBOJG6AIV%[@+:[W'WL<;
M=KY7EK&#9=UR0 2-%/E]U"N1_,:TRCV\7&7K&O#.E@K>GJE,/XRD049YAO94
MI9%DJU/=)SRQ 9&>L0.P7<&5"+914=Y+%/U8X.>![0O@VH((L*PVFKL9$;?9
MND>(TT,^*5<]AKNIW2MD&&4NL/YJDH^++6!IGEJ)M:5VON-:2XIC<SG3SOBI
MM8\510O<R"-FX/:TCCWC\:276N3[UK&V:(*)LVZRHII,FJK@I0.*:3)%5P4@
M_ XII(G6*01^!Q*!1^WG:QE>T!SI9&M)(#GRO:PN%KC6<X,+AEE<E<?U03;5
M!(SMJBXM?/9TW\JF!Q7YQ\B^(5MC9O5-_ES5EI)M%+)JR?DGLMKJSLT%2"[C
M)*MN7"B,(^7:@H@VG8$D5.Q:BA%TG"J13M%^N=/N"S0SA%P^>ET@PBF%=)!(
MVBQZC@BI\:H97-(CGAK6,:ZJB9(&NDI*LSTDX!8Z,/(D9]O",?Q3!9VR4E3(
M86O'&TDCC)2S-!N6F)QM&ZV39(M1[+@@D>],:+I8OION=QMPM/=_TV6^U6KV
M %Q<@P^F:PR4][#[2*:(N?8O>'LOM HHBX\GSA22$_EEYOAE'WNPS#<.XSCN
M]V'8?A_':G%\=[!HX*3C=36=J<;Q/&:FL[5UM76=:Y^3/)QT\\UM7CIYIM6]
M]7C972:M["^KK6O87M>PO9;DO02#OP25#[>\-JAZ?'U&N9YL]UM_6NS9^"F
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M_#T1P-F.XH(:@$T=-'[(JPTEI>S6U(X 6V+>.>??.!#A&R35<UVJ1O0T?6U
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M9N@7>!BV<5)6*3C&JKQ.DW [%!$+! V,$1CD%)$%WL!)+M)6,<I$1>-'O9G
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M2OGH=0RQKVOG-RQF'"PKB&\KM#H*"8#"#*K.D:JQ2 P&,'A1:0B*(% >Q03
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M'*ZW^T)5-A5DC&*1)1%=8QBD1;IKHF5<+G,!$6R) .(G7<*B1%%,H"8ZAR%
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M_P#ZEQG_ #J_-WGPGY+P[YE3?5)]2=Q:_P 6O0/^AO7/_AO'\H.GO^^^E_\
MU+C/^=3O/A/R7AWS*F^J3ZD[BU_BUZ!_T-ZY_P##>/Y0=/?]]]+_ /J7&?\
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M4R%*!2E   ,ZR>YTCG/D<Y[W.+W/>2YSGN)<YSG&Y<YQ))<2223<E?=
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M.\<U^-MKRQD:I@/FJIMV#J132 #&CQ4[IY;4/-VZE37;SJX*AWVF[0I]?O\
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M(>D*'QDU?N$:?#VC:6VJI'W*PW2SQ;&7E8U"4!06%8K0O4G)(&"BF::*!RL
M2>2[H%7LFX5#V1JREYN2-P.0Y/7;E1H  Y2-O2H-=<+15+U5^XIR6U? QE&O
M"MS?5RPOZNS;082LI#Q)[O2;&X0C4FR'OZ#?U^0;A+E2]M=-G31%TJJ2/:^5
M+#M!V=K_ ,%#\K'??;VZ%L0:ZLJUOUY1[>Z(1!>T4ZL6-P0O8A$59R#CY5<
M^P4J9W9^WKV "A]C,:NM=K@M283GQU .3/)_;$2WN5+UC,I-J!79Y!*2@D'#
MN8F(#6Z+B.=IJLGC.KTZJOIE%@JB+8UCFTYI5$7293&R.]ZT 'Q>7GVE4;8E
MQ.9O;,;NV7+ESJX;EUP]X^[\U#<6%XUW7DIB&K$Y)UFYP,1&0UPK$E%Q+MZR
M<14TS:)+*-06;IE=PS_VN'D$/$B[9'^0=.@)&P](W%6(!VJL_P"A_3BIISD
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M,W?'<\NW:LBIYZW.X[7]+6D^)U!=JI3&^K01U96K<ZB9Y.$C9J$K]4KKORS
M*L5-W:::OI%$0[+I5HC=3QH++$-=@VN.[L?(L;R<@-^[KR5F7'?AIHKCSJB%
MUE7Z%4Y@Z46@A<;--UR(E9N]SAT"%F9FPOI%FY<NR/WGGG:QJB@Q\6Q,A',6
MZ+9 I1J22;GQ<BN!8=0%^A4<<J*)$]-#J&Z&WMJ!G]*.G]P.E&UNJ$67V: 8
ML%IR*@=IUN/9^(6Z,&O'3D#>H2-$0:PD^Q5-'I-F31F@C<>^:0=HV'S??S*A
M&J01>Q.8'+VW+8FW7LAIJ#3NS]J/2HK-M>4&V7,45C""3Q2O0CV3:M1,00$
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MMW--M'LB(D13>O9%RFF)W:YQL_,!W+E]WG56WNX<ARZ#L\B]WU^#BEQYTRJ
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MAOEMW^I6Y)]_O#;?_F^D6>[?T9C;M'2/.KNV'H/F5;O0@^LUM7Y>;I^B6O\
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M"SMP-ZL47O"SQ^A.1\"WU=O<SSZ7HB2*T=P]5O%@9@*"\ ZBI40D*+?%E4C
M2MR!UHZ4=@HVB';9\HVA3'-MF#<9=N<=K*0Z^1R*NE,/< $/_>)_TRY166NO
MT3/X^.=W^=D3_:-MG,LNUO0/,U49L/3Z MB@_P# -_O3?U#F)76N#Q\_PZ_(
M;_).R_T(U5ESX#>GUJ@\-W1ZEL@9176N5U Q&6ZO?!>)D""I'-OW$1014%,4
ME/.W#;'RQO!W'MXW31L17S"@90$R%+W "B&1O@.Z_-R[50^&WHZ]_D/K6QKF
M-76O=]$#MT0U-QZDP\(/V6Q+TV:#V 5 0<T(SU<2>OB\ .HN/$X% 0$X)=Q
M?#WR1YDCEMZ5C?NY<[>3MVSG3S[E'W_HRMR2)E%1?/='U<KHX=P4$)9>H-I
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MR .$DQ52.3Q%&H:P$'6V<X4ZSO@^0J<'2)U+M;2W$Y:C[@I,_0+.VVO?))G
MV1-HE(#!RJ4"Y:2!2LGKY'V=X]"1%(?.*83D5\29?035>03EV[=:LT$#/^';
M:K1,JK)A$PB81,(F$3")A$PB81,(F$3")A$PB_)OAZ_ ! W_ "1 W^KTPBUN
MNF<]0T=U+>96@)Y4L<YMC^\*UE!<!2&37J5]?W**1;%-X?&=Y1KDZFVP%*/F
M-&3I8G[V41S([-K7<FW9O^\9].ZV=!X3N?8.B_B[6N++9"75312.JJH1-),/
M-444,4A")I]CJ*'.80*4A" )SG,(%(4!,80* CF-76N-T/5D7.[N;+ANJDX;
MN)6N.&ZZ"A%4%T%[_LY5!=%5,3)JHK)'(JBJF8R:J9RJ$,8A@$<DF[K]"JW\
M;^T?0NX=<ZK2]8=\4^1\,R<."ZWODE 2:R11\"+Q1]7K_543F* ^ 7SJFS;)
M,Q_DBLLDF4/$H/>&'PARCIV<W7Z-ZA^6J>0_?Z%>Y0+E6MDTFI[ J3MM)UFZ
M5V'M,$^0,DH1S%SK%"29G\28F*"A4G )+)B/B273514 JB9RA38K[5[)2R5=
M&QM:@I.P2=L>P[NPLJR>28$L#J!CWC6/>SC:',L$BM$,W[YFR<R23<S1!VZ;
MMU%BJJE*)%AGEQ]:OR3_ ""[=_0.=R6[1TCSJ';#T'S*MSH0?6:VK\O-T_1+
M7^6?M'1Z2JLV'I] 4:]K.V$+UZM7/+64$XR2AZ4SKJCP?"@+^4U!;86"%L)P
M$O<]H]K9MR%#N:17\!1!10 R1X!RV'T@W[<B')[>CSW"V.1$/*_&3T#[?<OH
M !]D1[@  'Q$0 ,QJZUS^([IJ]ZVW+1PS<MW;<U?VPD"[99-PB*K5_J-HY2!
M5$QTQ4;.D%VK@@&$R+E%9!0"JI'(7([P&]7F*HW:[I])4V.M#]8C>/\ /S4W
MZ=1N59X0Z_,5+_!/5YPI%=.KZQWB[^1VI_\ 9U<AVT])\ZENP= \RKPZ_/UM
M&I_RSK?V:7;+,VGH](57[!T^@JWC2[%&3X^:HC7'?R)#3M#8K"4 $02>4:(:
MJ" #Z"($5,/8?3T]<HKJC'H<SR>M]F\M^-5D 8ZVPD]&3;2-<F!)4WT@S%@U
MY;$R)J"4YU&*AZRLH!"B/D/"+#^]B ADDSU3NMY\_2?%F 51NUW3U]?-R=:O
MXVLZ:LM8[$=O7+=HT:T6WN73ITNDV;-FZ-=DCK.'#A<Z:*""1 $ZJRIR)IE
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M*?OW^1 "?"W;NWBSOE??FM@1!L@V;HM6R*3=NW321;H(IE21120*4B*221
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M3_\ :5C=X;>KSE;&8"  (B/8.YO4?QCF)9%B;7V^M)[9EYJ!UAMG7>PIFN)
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M3B9HC:EE6%S8[/0(SZ9'IA#QO[%!+.JW.R*@%^2121E(9T_5(7L4JCDP%*4
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MZ'1*_9'K-'OY+"8=LB)SL<EXC&,*<?-HR#),3&$W@0#Q=ARA%B1ML2%=0]Y
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M2[8>@KJ72"DG#_@%I=-P83!%OMEQ+<1$3=FC/9ML]F( =O0$TU02*4._H0!
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M*)Q(4B;A;Q' AS=C-C]WO3YB1Y0%+[W;8[3ZK76QH@FFBDFBD0J:2)0223(
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M["ZC^E.8V\*>[#2UXVC,T[4+FSME20-<I]:?+T6 F84XB#=61U_8[+$VBQN
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MY_*5L@"( 43?$  1]/7N';O]CO\ T9C5UKAL/*W?UY'<A!"9]":4BUTYEX@
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MG6CP3:PY?0KF:^@LV@H9NX3,BNA%1J*R1^P'3529()J)F["(>(ARF(;L(AW
M>PC\<HKKV^$3")A$PB81,(F$3"+CL'?OV#O]OL'?^?"+G"+@  /@ !^( #^K
M"+D0 0[" "'VA]0PB   '8   ^T'H&$3X_'"+CPA^'X=NW<>W;\7?M_1A%SA
M%P( (@(@ B'P$0#N'XL(N<(N/"7OW[!W^WV#O_/\<(N<(N.P?A#X_ 1 /7X^
M@" #^?"+D  /@';\6$4"NI]Z\">3?;[WG_YB@<O'X;>E5?X)ZO.%B[HY>$W
MK5IBB4P#9=K"4Q1 0'_YR;$ B4P=P^(" B _$!#X@.0_PCU>8(SP1VWJT4
M/_U$1$?Q=Q[CV_!WRJLN<(N! !_F[=P]![?C#U_IPB=@^UW].WKZB(?:$1[B
M(?CPB  !\  /Q!V_JPB" "("( (A\!$ [A^+"+G")A%P( /H( (?:$.^$7(
M >@!V#[081,(G8!_U?;#\0_8_-A%P!0#M]D0^ B(B(=_CV$1$0[X1<X1,(N
M  $1   1^(@ =Q_'A%SA$PBX\(?F[=NW<>W;[7A[]OZ,(N<(F$7'8/Q>O?T$
M0[C^'L(=_P ^$7/8 ^ =OL_G^WA$PB81<" "'80 0^T(=P_F'"+D  /0 [!]
MH,(F$3L _P"K[8?B'['YL(N   _#V^'<1$0_$(B(X1<X1<" "("( (A\!$ [
MA^+"+G"+CL'?OV#O]OL'?^?"(( /Q !_& #_ %X1<X1,(F$3")A$PB81,(F$
M7A^\&/W6U^<H?K,_%WQH/CM)\ZI_K5779\)OZP]:>\&/W8U^<H?K,=\:#X[2
M?.J?ZU-=GPF_K#UI[P8_=C7YRA^LQWQH/CM)\ZI_K4UV?";^L/6GO!C]V-?G
M*'ZS'?&@^.TGSJG^M379\)OZP]:>\&/W8U^<H?K,=\:#X[2?.J?ZU-=GPF_K
M#UI[P8_=C7YRA^LQWQH/CM)\ZI_K4UV?";^L/6GO!C]V-?G*'ZS'?&@^.TGS
MJG^M379\)OZP]:>\&/W8U^<H?K,=\:#X[2?.J?ZU-=GPF_K#UI[P8_=C7YRA
M^LQWQH/CM)\ZI_K4UV?";^L/6GO!C]V-?G*'ZS'?&@^.TGSJG^M379\)OZP]
M:>\&/W8U^<H?K,=\:#X[2?.J?ZU-=GPF_K#UI[P8_=C7YRA^LQWQH/CM)\ZI
M_K4UV?";^L/6GO!C]V-?G*'ZS'?&@^.TGSJG^M379\)OZP]:>\&/W8U^<H?K
M,=\:#X[2?.J?ZU-=GPF_K#UKI&QZ1KS;E*G]=;%C(NT4JT-D65AK[UZ9)G+,
MD'K60*S=F9NVS@[51RS0%PB58A'"13MU@.BHHF8,2H!LK:3YU3_6J"YAR+F_
MK#UKWU?C:E4X6.KE785^N5^':ILHJ#@F\9$Q$:S2 02:L(Y@5!HT;I@(@1%!
M$A"]Q'MW$1%WRH/CM)\ZI_K5.NSX3?UAZU[GW@Q^[&OSE#]9COC0?':3YU3_
M %J:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_6IKL^$W]8>M/>#'[L:_.4/U
MF.^-!\=I/G5/]:FNSX3?UAZT]X,?NQK\Y0_68[XT'QVD^=4_UJ:[/A-_6'K3
MW@Q^[&OSE#]9COC0?':3YU3_ %J:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3
M_6IKL^$W]8>M/>#'[L:_.4/UF.^-!\=I/G5/]:FNSX3?UAZT]X,?NQK\Y0_6
M8[XT'QVD^=4_UJ:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_ %J:[/A-_6'K
M3W@Q^[&OSE#]9COC0?':3YU3_6IKL^$W]8>M/>#'[L:_.4/UF.^-!\=I/G5/
M]:FNSX3?UAZT]X,?NQK\Y0_68[XT'QVD^=4_UJ:[/A-_6'K3W@Q^[&OSE#]9
MCOC0?':3YU3_ %J:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_6IKL^$W]8>M
M/>#'[L:_.4/UF.^-!\=I/G5/]:FNSX3?UAZT]X,?NQK\Y0_68[XT'QVD^=4_
MUJ:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_ %J:[/A-_6'K3W@Q^[&OSE#]
M9COC0?':3YU3_6IKL^$W]8>M/>#'[L:_.4/UF.^-!\=I/G5/]:FNSX3?UAZT
M]X,?NQK\Y0_68[XT'QVD^=4_UJ:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_
M %J:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_6IKL^$W]8>M/>#'[L:_.4/U
MF.^-!\=I/G5/]:FNSX3?UAZT]X,?NQK\Y0_68[XT'QVD^=4_UJ:[/A-_6'K3
MW@Q^[&OSE#]9COC0?':3YU3_ %J:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3
M_6IKL^$W]8>M/>#'[L:_.4/UF.^-!\=I/G5/]:FNSX3?UAZT]X,?NQK\Y0_6
M8[XT'QVD^=4_UJ:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_ %J:[/A-_6'K
M3W@Q^[&OSE#]9COC0?':3YU3_6IKL^$W]8>M/>#'[L:_.4/UF.^-!\=I/G5/
M]:FNSX3?UAZT]X,?NQK\Y0_68[XT'QVD^=4_UJ:[/A-_6'K3W@Q^[&OSE#]9
MCOC0?':3YU3_ %J:[/A-_6'K3W@Q^[&OSE#]9COC0?':3YU3_6IKL^$W]8>M
M/>#'[L:_.4/UF.^-!\=I/G5/]:FNSX3?UAZUY*:B:I 42.10@]^QR&*<H]A$
M![&*(E'L(" ]A]!]!]<_5'+',P21/9(QU]5\;VO8;$M-G,+FFQ!!L38@@YA2
M""+@@CE&87[RZE,(F$3")A$PB81<" & 2B'<# ("'VP$.PA^<,@@.!!%P001
MR@@@^,$HHV'X@<;5#F4/J>OF.<QCF'VF<#N8YA,8>P2P!ZF$1] [>N:QO[C3
MN97N<]W!)@.L]Q<XBNTB:"YQN39N-!HS.P  ;   OB>US [D][H+DDG.3,DD
MD^'O))7Y^H\XU_>FK_SJ=_:^5]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU
M_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7]Z:O_.IW]KX]
MQCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:^/<8]S)^23 OI#2/
M[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY
M/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7]Z:O
M_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:^/<8]S)^
M23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^D-(_MM/:
MY@?R=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3Z
MCSC7]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:
M^/<8]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^
MD-(_MM/:Y@?R=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)
MT'CD_?3ZCSC7]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>
MFK_SJ=_:^/<8]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QC
MW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^
MVT]KF!_)T'CD_?3ZCSC7]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/W
MT^H\XU_>FK_SJ=_:^/<8]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.
MIW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?D
MDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@
M?R=!XY/WT^H\XU_>FK_SJ=_:^/<8]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-
M?WIJ_P#.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_P ZG?VO
MCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7]Z:O_.IW]KX]QCW,GY),"^D-
M(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:^/<8]S)^23 OI#2/[;3VN8'\G0>.
M3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK
M_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7]Z:O_.IW]KX]QCW,
MGY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:^/<8]S)^23 OI#2/[;3V
MN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^
MH\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7]Z:O_.IW
M]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:^/<8]S)^23 O
MI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^D-(_MM/:Y@?R
M=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD_?3ZCSC7
M]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_SJ=_:^/<8
M]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY),"^D-(_
MMM/:Y@?R=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]KF!_)T'CD
M_?3ZCSC7]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_S
MJ=_:^/<8]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]KX]QCW,GY
M),"^D-(_MM/:Y@?R=!XY/WT^H\XU_>FK_P ZG?VOCW&/<R?DDP+Z0TC^VT]K
MF!_)T'CD_?3ZCSC7]Z:O_.IW]KX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H\
MXU_>FK_SJ=_:^/<8]S)^23 OI#2/[;3VN8'\G0>.3]]/J/.-?WIJ_P#.IW]K
MX]QCW,GY),"^D-(_MM/:Y@?R=!XY/WT^H]XU_>FK_P ZG?VOCW&/<R?DDP+Z
M0TC^VT]KF!_)T'CD_?6;Z=3*QK^O,:I3HAM!5Z-,Z,QBVAESH-S/7:[YT)#.
M5EUA%9VY77-XU3=C*& OA* %#O70O0G1;@[T<H-$=#,'I\!T<PQU6^@PNE?4
MR04[J^MJ,0JW,?5SU%0XSUE543OXR9]GRN#=5@:T?3IJ6GHX64]+$V&"/6U(
MVW+6Z[B]UM8DYN<3F=_(NSYRI?H3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$6&]Z[_ -3<:Z&KLK<]L1IU/3EHV"+)*1\M++.)>6,M[$P9QL(QD9)X
MX42;.W2A6[50$&;1V[7,F@W4.60"38"Y0FVU91A9F*L</%6""?MI2%G(UA,1
M$FS4\UI(Q<HT1?1[YJJ  "K9VS<(N$% #L=)0IOLY"+V>$3")A$$>P"(_8#O
M_-A%$*Q\[N+%6WS#<:)3:3,VY)NP0]4;U:.A+'+)-;-/$24BH&4G(V*<P49*
M.4W#<RC5W(IG8@X0]X>RBJ4!G5-KVRVJ+B]M_0=_\5+WXY"E,(F$01 /C_Y[
M^@?TX18)U%R7TEO>P[+JVJ;VPMTYJ*PEK%]9LV4LT+$RAU7[4GLSJ18M&LRP
M.^BI:/)*0RSZ/.^C'B!7 BF43R01:XVYCMUJ 0;VW9%9VR%*Z_:K57*/6YVX
M6^:CJY5ZS%/IN?G9=RFSC(F)C4#N7S]\Z4$"(-FR"9E%%![]@#L "82E$B]-
MK38]1V[0ZOLJA21YFFW.*1G*W+*,GD<,E$NCJ%:O2LI%!L^;IN2)BJDF[;H+
M^48AE$DS&\(-B;5WG")A$PB81,(F$3")A$PB81,(F$3")A%@G5_)?2&Y[OL_
M76M+Y'VBXZ<F206P8=LRE6AX=^9T]CS>SN9!BT9S+1&5C).)<2$*N_8H2<>Y
M9JKE4*GYDV(L>78EQRK.V0B\9Z]9QK-U(2#INQ8,6R[QZ]>+)MFC1HU2.NY=
M.7"QB)(-VZ":BRZRIRII)$.HH8I"F$"**>A.<G&/DY=K3K_26R$[M9*A$&GY
M=%O7;/&,3PA)1"&&5C968B&$?*,C2+ILBDJS75%=-=-T@51J8%LDM(VBUU%P
M<KYCMV^]2UR%*81,(L$0_)C2$]O2R\;8F^Q[S<]1KZ%EGJ:1G*D59QJR4>Y.
M5.658DA'D@S9R\0]D(IE(N)%BSDVCARV33,J*4V-KVRO:_.E\[;]JSOD(F$3
M")A$PB81,(F$3")A$PBZE?;O7-:4FV;"N#\(RK4FNS%IL+\2&5%I#P3!>1D%
MDT2?OBZQ6[<X(-TP%5PN9-!,!44* @+FPVG((JDJWU:K&]5H=XMG"S>E4XZ[
M/M,?5Z1N=NNULRTBM-/S1D&[7I<1$F<B$FZ*8$&,?+/7CP$UDJ_],+E,J"U]
M3D<"0+D<G7VW7LJAU]QMN/IMR<ZF[LGEK%ZZY4:!XOKTB5EI#?,#;YUC<4)A
MBTCJVG4FD@Z4;OH=PU._?J/@8"1,S=PA[.94OG$-X#!E0+@F^RV73V_ADIOF
M!RW\G;F3:O+2,U=R>X\<:'-(E)B0Y L;@^8VYM,L&D=6 J+19TJF^BEVJCV2
M%\5'P)&:.$ 1$P&4 P!Z@+@GDMY4)L1EM-NA1]WAU%;'3]T7C1O'SB]LCD]:
MM314;*;:>U"89P<13CRC0K]K#H*'BYIW-2_L:J9E6S=N@H=T5=A'(R3EF_!K
M(;E<D"^SQV4%V9 !-MO;H] WK(#3G]3Y?A-:>:$+KF\#$5&,D%I77=A32K%B
M-,P\\PKLM&,I=\V7B)!B@^?"9I/L2.8]V1!9LH1K)-WS!FU3K:MQT]5_,IN+
M7W**KKJ\6*-K-9W'+\*-YP_&:67@6DQNR0D8M-O'*RAV[1\^B:\2-'WY LI1
M1:/C9E65BFMD41*6..D]=-&"LZFWWPOR;SY577YC8VS//X]WJ5A/(?EKJCCG
MH8>0%D>N[#5I5M _2+'5HB;B5V!*VUJ5Y58JN%<F00,>69F-)'=.#IH,8EN\
M?K ?V<$%:@$FP_@K$@"Y47=&]1R8N>ZJAHKD'QHV+Q<M^T8MU+:E<W65;2\/
M=?94#NCPYG/NF#6BIM1LFI[.T41<B+TI(Q^2+D'4>W?26Y7!#K;;;NKT^A0#
M?:"+[+[[>;=M7E<D.HZIHCD0AQIK/'79&ZM@S-$A[94FE#EHGS9Z3F7$F5&$
M7CW#)9Y%1[)G$/I"6LB@NFD>V3*91H)!.JF#;BY( !L;^?[O%="2#:U[C+=V
MR7;>)_/)3D!M&^Z$V?I*X\=]Z4&%;6AW0;;*-)HLO6'*K)(TI&2B#&+$RK4T
MI%+*MQ:*M73"1:R$9(OD2O"-!;:QO<'>@=>XM8C<L)[&ZI-@CKIMN.T=Q)VI
MO[6NA9Q_7-K;6K<TQB(:)EX3S!L*4+&&B)9U,-80K=T==X*S?QHMSOU&[6'.
MWDW$ANRY )V#L>W2A=:^1(&T^?Q>O99=SY<<H>/\[P+@^1NQ=#R.Z]0W1W0Y
M9EJ^\,6]5FB.9B350C)!TE,MW*;)U$N4ECHO&)UFDO'K>?%R#V'DDUG, $.M
M>QO:X-QEYU)(M<C+D(ZMZD'R(Y::OXF:(K>RK# R#A.=2K5:UMK"HH,QG;)/
MR\2DXA:I M@!%DU:Q[%/^['@)>S1[%J!&S5T[681SJ "XV'2>8(2!M4>=-=2
M&9L&ZJ9HGDCQEV-Q7M^TFJBVJGMSE6TY W!Z0H&)!'>DB892+F7 ]FS9N9-V
M 2:K:)DB1;]]'HNY+1:X((WV4!US8@CMV\J]]RDZB1..&^ZOQZA] [$W-=KO
MK]M;ZDTH,G%^VR\R_E9V,CZR,0Y9K/4$#>X'3V3L!3+MHI@)G*C%8J"H@#;@
MFX '+_!"ZQ L22O8\6^?CG=VX[9QUV]HFY\;]X5RMIW)C3K9+LY]M8JSYC<C
MIY'2C5A%B5TU(]9N00*U=,7S$SEPPDEEH^0:-A;;,$$;+\ZD&YM8C?GR?Q\R
MGK<)F0KE2M%AB8"0M<I UV:F8VKQ)TTY2RR$7&N7S.OQIUBF2)(3+A!..9F5
M*9,KERF)RF* @-5*UWNFYMFVS7+7DZ,SQ+O$JXVUR/4G+G<)5*O2!^-,DT2M
MTXUKEY=NHT[SWHSE2%9I+0JC B4FFFN0A!*3,CQD,P0!8<_./(J--R<MODYC
MVVWY[3_W/U'9JN[FN>C>-_&38_*:W:K:(K[8>4N4;0D#3'JI#*# D>GB9E67
MFT0*9NX:I)->\@DYBXXLH_8R*+.H;E<D-OLOY^A3K;@">6V[[\LN59^X[<TM
M=<DM"6?=U-B9J,=T1"S-+WKN>.U:VBJVFJPZLP^KS\Z?F-CD>-B)K14J1,J+
MENMW7;-'S5_'M((L;'Q[E-[^KGY%"O4'5:V5R""ER6F^"NY+94I6TP-3N]U-
M98].KTJ1G9MDP,))6.KDBA--X2(?M9VPNA+'(PZ1Q;O111#V\\EMKW<-]MM^
M8'DNH#K[ =USEE?SVY+=*N:[^GJ'V>W_ /=V ?\ 6&55E7%Q&VSI"?NO-]35
M>@8O4\[JO<$U"[.FXM>(\_;-DAD+&X-9#@Q:(&C2+J1SY5-BY\PB3N5=O!(+
MER\56L;V;<WRRYAR=O0H%L\K6.?K[9\JBS5^L)?=F4![LG47!#<]]J=1;/7N
MS)]"U1",!44&28R!V[&685^2-8GB,$*<O+HM6*!X1%0@.D56X^V9.INUA?<.
M7U>6_C5=?*X![;=ZR9RVY91>Z.F=:-R:AUW<+W6MR4JRU&>;,E(]K)ZE9JQ-
M@96BSW5,!>(*Q=+FH88Z4+'+#[:5XS>L7/LJZ:H@+/ )V'HOR=%^?9Y%)-VD
M\H[>)>7TM=[;!LO'_7FNK#QVV+1*5K?2$*^K6XY][&J4S:)F3@6Q4:N@@V3>
MMSNFQU9-(7:BOA:)F P&-V.,/ !)#KW)RWCIRV[CNY-Z-V 6W=(RMO'+ZUC[
M7'5MV-N]BSD-(<$-T;#8,;$U@;S,,[-'?2]4U)&3:LXX$YF,K4H64<FCW03,
MPW!JT&!8D*L[%5JH+Q.2VU[N'-RGJ_B@=>U@=MCS=NI2:Y!\W=H:TVU)Z8TO
MPYW1R$M-<@(6RV>;AE&M3H["-L"*ZL7[KLKUA*(S;E4S-\U52!)@)'K)VT0*
M[6;K G  M<N OUGK S"$F]@+\N[MVYUZW6'48@=J<8-Y[Z@]17%E>..HS3?:
M&CY:48L;-%OH!$DC((M9M=@#91N$.E)NR*/HIB^2>PLG%/8]JX0*J<6V(%QG
MF#NMV\N2:V1-CEN[>7D6>H7EE29CA^GS"".=M:@.H7VU%J^H^:GD45(Z+<N'
M55]Y$3]A/)$F6JE?([!(&YW@E5\HJ8^ (L;VWWLIN+7W6NL-S_4.I=*X=ZZY
M7WK7]G@GNVDV#?7.G&,@PG;K:9V?>2)*Q#L'K=LU8C[TBF))]V^!L=*.C'!$
MRI/Y!1HS>2&DFV669.X ;?$FL+ YY[!;/L=R]%Q\ZA4KL3=D;QYW[QUO_%W:
M5NKKBTZVC;K*-IJ*O48Q1<.G[1E(IQD.=G,MVC1XX39&;N451CY%BNX92S8D
M>X%MA<&XWJ ZYL18[K[_ %+T6]^I2^U1R3L_%FC\9]E[LV;'5FM3E7;4F;AT
MT+&YL$8VF7"#]%PR5<UN(@XQ5PXD9]T+QJ"J*2 HH%=%71D,N-:X N!GNVY^
M39T636%[;>CQ[[;EE#B%SG;\E;CLS4-YU';=![SU.DQD;3K2VOD)A92 D3HH
MH3,9*-V,:98B"[EB1ZW78)$*A*P\A'.Y-A($73@MM8[0=A[=8ZBI!O?:+;BL
M8;BZD4U!;CO.E.-O&+9/*>R:D23';4K3)1M"5^GR!BG.I MW9XF:7F)IN*:K
M9PU30:F/(M7L9&)2CQA($: W*Y-K[.?MVW7@NS( OT=-K'D4@-"<U=<<B..]
MJWY2HN9:J4.-M87C7DV=JSM-8M-/@U9R1K$@H056HB[;$15BI8A/9G;1TDLJ
MW;.D'K!K!!!L5-]X[>->TX\\K(WD!Q7CN4#&E2=8CI&N7BPEISZ88R4DD2E/
M)UHJU-+M&J#$QY 8,ZB*H-@(W*X(54IS)G[R6V=JW!SM?<EQ:^ZU_$L/5[J.
M:V=\($.;MNI]BJ=8>K2<9&T-&0C)ZS2EA1M+NIPT%'O421\8JYF7[;V@7"H(
M-XV/!RZ=&.5H<#BTAQ;OO9+Y7SV7Y^W8KI>E^HQ>+?N/76G]Y</MQ\?7FY&K
MUUJRQ22PW.&G/8V022J4T6-@8QU7TD&(IJ/WBI')(11RS-86T.R<D>@+18D.
M!M:^T;>3ES]847S (M>^\'8K2?00#[0@ _\ G[0_U9565>O$K8^DK=O'G%%Z
MTT+$ZMN6L=K-*[M*Z,%8E1SMN<'Z:#ISZI&+5!>.(5:*?NE&;DR@+/I5P_4
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M+-K&2A%5FHL';8J=@=,GD5(,!$WL$I#2#5W%2;$#G(U>LUTDE%42IJGAH(<
M<CGYBCO!)Z/.$Y9]YSFKTCZE,)@M6$E9RUI-EA+[(M98B!JSJ-6.F;Y"B[1Q
M&1QT@.!C"*A2I]A$>X>"[J\Z':W+E\W:R[5UF44HS6O%J\1I02NE3Y9ZV/5G
MR(@5\BI(-)-T^2;' 04 KES#Q*JP$'PBJU;** 84R]I9OW^].7*CA>W2,]XO
MV"\S8P=^MIH4!#_ZH=S_ .\[T'?\'IW#\7?[ C@> [I]26&M?> +=>LO V5^
M]];GCSY?9/SN*5Q(KX  OFD(79!B%4\/;QE(8I3%*;N!3  @ "&2!_-N/(X*
M=XZ#YQZU<\/P_.']89C4JG/IC 'U0/4Y] ^NR<^O;X?W7<Q]/M=Q]/S]LL[8
MT;M4=O(JM_&_M$>*R\7HTHI2FM.4EYDA!Q<[9RWV:>TO5@$SY52/90[IBBZ4
M/^^'!NYF)59$##V34=+]@!451&7[0-P'I*-WY;SVO<W[=)QQQP33@>5W6.JD
M)V2K"T6VM"S- A0:(V66J5R>2BJ8)@"2*ZKJ5DA6(4H'.81$_?RP ).88#V%
MQR?Q3>[JVG*]O(-BDGT:2E#I]Z<$"@ C)['$1 .PB([ G^XB(?$1[!W$>XB
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M0F9() %CO-^V[H68M7%+_P"FMY+@  )0XE4( [A_M1>:[#MZAZ@( '?[ ]@
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M  ,/\(\RAG@CGOYU'CI]^O2*Y:D'^ DMRI(D3_:I$#7C$X$3+\"$ YC& I0
MH&,(]NXCEG>&.>WGMZ%(V=;O.5*/B/\ X&Z"_DK;C_[!L7#O](?[0]"-V#H'
MF7B\&?\  ZUK\@&]_P#MNS,/_P!*?[0]"J/ ZG>E8/XT\6R\ONC;IC4C2PDJ
M=F17G;G1K$X(LK'QMRK&SKFM$^]DFP"[&*?).7L8]79@=XP(]"2:(N7#--LM
M+CJR.//;S*0+M Y@LU\6.;^WZQN&L\/.=>O!HN\Y%FJRUQM2/!!>G[>313/Y
M9B.FY08HR\T6.4\B5AE@BIJ40&,DXBKSAFD6ZJ6BVLW,<F\=K\_2<[ 3>Q&?
M-LMX^8K\:?$!ZT7+40'L \8=9" _;[EUIV#U^W\/SX/@-Z?6H'ANZ/4O5=&E
M).5USRKO4F'FW.U\N-EFM#U8?$]5/',8AXQ3<G/\LP-G4U+G2\7R2J+KB4 4
M\T1/V@<C0-EMEU+=^S.QVW-R,[]?I6-^.92P/+7K&U.#("567A4+4NV0$@,T
M+1*U2WNY(Q$B !$W#AS+2:BWA IA-W*IW$I?#!/O6?WO/V[!!M<+99'QC[O.
MLD]+!-,_2U8E.0ARFBM^%,4Q0,4Q3RMH X"40$! P"(& 0[& >P]PP_PCU>8
M(SP1U^<KN?12,8W B@%,8PE3N>S4TRB(B"9 MKHP$( CV*0#&,(%+V !,(]N
MXCDOV](]:AARZ#;S*V;**Z81,(F$3")A$PBQ[M>%OUBUM=X/5EM8438LK6I5
ME3+?*1!9V.KUA7:G)&R3R*,<@.D$%_"!ODKBW$P.@9OA0!FX#:+[-Z'8;;=R
MHYVKK3JB\L=50O$3=FDM7UF#"=J7T_<FCWF%E4YB&JTF@\2L,-5HUX=V6QOR
M()K.C1\6R/(KK.&HQE8;/G8L+W:#<$GD%K6Z?N\JH0XY$#=<WV]61\W2I1<W
M^,>^0V%Q4Y*\5X2*OVP^,2,C6'>OK+.-892X4N2CFS,P-I%\XCV!GH-T9-E)
M)&?-'1R2R$A'"X7C18NH!&8-['?S_>I<#D1;+=V[>(+#%?U#S_WMS=XN<F]Z
MZ5H>K=?:M+;XX*I7]A04_/4Z*EJ_,MUW]C4.\%W/R=CF'L:#9O" LA%1S  <
MM&:YUU7D^\#7 $DDC.V5O'N-\_(HL20;6'(23RY[+9;NULX[7L?5 TYO#8\O
MK/75"Y4:2OJT:ZUW KV&%US+ZB6;M 9A$OP<O6+R5:BJF=U*OC.99&:/Y#YL
MZK"YW,6,#5(%[@C;OOVZ/'M4^^%]]]FZW3R_=SJ+=NXQWSC%TE.8,;M9:"#8
MVTY"Q;;N$'5E"K5VJ/+-9Z:BC5XIPB4C9R$>W8^-RNS[L4W#D6+!9TT9)/7-
M@;O:1N%@>@&R@@ZIV YD]>9\F2Z5$0G4RWSQ"UIQ08:;U;&:LV-K'6\0WY)M
M+RR20:Z9=QL*_8M)BG>V!*M[6C!I-(F=!C&JK2)4GB#2/25?A,(O>AQ-S<&]
MK;^8\@/F4>^+0+#,#.XR&ZX-^G+SJ??+3@K,7KC#I/7^@YAE!;7XH/J-9]'R
M\R<C%M)2E%C6L:O&2CLA5T8]:R),T9('BB:C-.=:,B/A)'*NE4ZAUB;Y@WOU
MJY%[<Q!\2]7J&Y]4+;6U];*[-U3JOC)J2E2*[[:)!G8[8<[MKLQ78*PM=:,)
M5^XK3!1PX+*1SKVYL$8Y01<NI2Q(MQA'8ZH!L23NRR'3S]LD&M?8 .F]^C[U
MV<_';;0]4%+DJ%>9#ITO&H^NC63W_#^W!;1EA=!'!71<^^Q1%$?%[P]E!GW^
M2*OB],7&K;?K7ZK*+'6ONU;==US)\=]LN>J#6^2J5>9GT['<;'VNW=C^F"'(
M^3MB\I).4XXM>%U[Z.B9%PD;W@1J+,HF$HJ^(H@"XU;;]:_593O!Z0>NWJ[;
M1@2\2/5GH<IN35S?5>L.4E+V3+6HFN]HN+%7:(VI%<M31=FC!3]/=R+)1>-@
M6+DB18Q^#[Q.BO!&S3C%T1%L][EF01MR/C')VR4&^>0(Z;999=O4%U7:_3WW
M5%=*NJ\0M?MH:_[;C;+ VF;21GXZOP)W[VWR5HL+:+EK$I'(&80I) C!JLY!
MNO*&;'=IM6X."MDIUAK:V[[K#QIJ^]U>U[W4F.;'$O:>XM;Z O>E7\1#<D.+
MT_7[MKY";=-T86<7:QL.A8:B\D3>)HB#YU#1[AFX=J!%N#LW$<\79M)560:P
MTVN#L=MRS'.$<+V(VC,<ZCXVTWS;YN;RT18^6>H*=Q]TAQZM2>Q5*?%7%C<)
M?9FP8L$/=9R)Q[^2%G").6Z(]GZC9)C#K2C1NO-/Y,J\?-V@&Q))RV96\GIZ
MDS)%Q8#/:#<[E)*Y<>-LS'4]U+R38U]DMI^J\=;+K^<L9I^'1?-K5(OK4NT8
M)UU1T$TY143E&8B^0:G:)^88#J@*9_# (U"-Y/DR]2G._-89\X)]:\2\<<]N
M375"TUR5CJZR6T[4-!66BSUD-8(9%\TLTB2[ T8IUU5T6:=I*#,Q_=ZV:G:)
M^<?QJ!Y*GAD.&H6[R0?%V[;F^_,?+;U*RX?]8?T"&44JM_@UQYVQI;;W.:U[
M&K[.%@MU<@7%\UP[:ST/,J3-9.O95"/W32,=+N(=7M(LQ]ADRH.OWPP"G^]G
M MG$&UMP *@"U^<DJ-"VF^;O"'>.][!Q-U#3N0FD>0UK5V*C4Y:X,:=+:QO\
MH+HTB"B;^1CA>09W+E7N+$[E)_#HQ35=>$?QRJ\C-VN N;$99#:/+GY-_,HS
M!-A>^ZX%OX_QNLZ<1.(6U]4Z=Y+6W<+^'G>2_*QW<+=?&T([;&@X9[(P4\SK
M%.9R9@39G*P>3C]9XZ;J>ZFAWR4>S7=L8I*1=P2+BVQN0Y\[WZ3R[?,I M>^
MTYGU= W+*G37TALGCMQ!UMJ?;4(TKUZKSZYKRT4RF8N?;MTYBWS$K'B24AW#
MF/<"LQ=H*F!%8PI&.*2@%4(8H'$%Q(V(,@.@*=X_ZP_H$,JI57W$'C5N+4]N
MZ@LK>JVQBF6^=T6FX:P5;V*$E#3M?DVMM29/':4>[64A%%3RK$#-)8K9RGYI
MA.F4$E/#9Q!U;;F@'IS4#?SGT >A=FZ<O'S:W'SA;$:>VM7V=?V U?[*77B&
M<]#SS8B5BEI!U$&"6B'3F..+A!=(QRE7$6XF$JW@,40 X@DD=LD:+  [K^=8
M0XH\,-TT[IJ;:XN['AXJH[/O#+<[.)9_3%$ST6DK;V"1*VL]F()=\T2;.7B*
M9'GEBJNS1$ZAT3& I#"1K7&RX/B4 '5(Z1X_XKO?3T8\RZKK)CH;?F@ZYJZC
M:HU6%/J=O1N\18;!>[*W?*-&9!BH:7D&43$MX51=1R_/XROWIFRK=1HF99F4
M[5V@DDGDR _BC;VL0!86V]NW2N]=+[C_ +5XU\7D-:[B@&=;N2>QM@V$T:RG
MHBQ(!%3TFT<Q3CWC".73(3KI)',=N"WG("'A5*41#N<07$C9N4M%@!VVJ+*&
MJ^='#WDUR8LO''1E-Y :KY07)'8L<XE[_%TA37]T=FD7#XM@3?/4'QHUN^F)
M$CH&2#A&5C$XA=M)1[]!^R--VD"YL1ELN"-W/?EW"^5U%B";"X)OM L=ZS+T
MVN.O)'2MTY@7/DC U:*L>\MGPEY92%.G8V5@)QV<]Q>6%Y%,&KA62A(LCZ=;
MEC64VDVD!:G*"J8JI+"$.(( &[[E(!&VU[[EC:6X!;$>=4N.Y&)13(O'8SR-
MW')')88Q,P[KAJ&\I;),:N9?WJJZ,^!G8??16@M"$4<M_:2JF,GDZPU+;\QL
MW$WOS\G*JZOOKV%ONV^/S^*2'4'XN;(WQ6M3['T/)149R!XX;":[)UB6=72:
M1$^)19C,U=\\6#V=L:3/&1;IJJ^.G'+*L5(U^NR:R2K]K#2!<'8<B=X5C?=M
M&8\WI74M'6WJ8[9W%2)O;NL=9<9=)U!O+_3U5R3<?L.T;7D'<>9FU;Q2K&1=
MN*NRC7XI2D<\%XR3:D\]%W]-/FIMVHZH&1)/FSZMW3U*!K$[+#?G>Z]W0^/.
MV8/J<;MY(2=?9(ZAN?'NI4*OV,D]#K/7EIBG%.4?,5:\DZ--,T4BQ#\2OG+5
M-HKY1 34$54_%)<"QK=X)/C\GE2QUB=UK;=OJ7YJ''C;,3U/=H\DWM>9):?L
MO'*O:^AK(6?AU7KFUQ[^L+NH]2NINAFFR*:<:\,#]=J1HH*92D5$5">*"1J
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A1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>srpt-20230622.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-22T14:19:21.5861+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.sarepta.com/20230622" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srpt="http://www.sarepta.com/20230622" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20230622_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20230622_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>srpt-20230622_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-22T14:19:21.6446+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="srpt-20230622.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>srpt-20230622_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-22T14:19:21.6476+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140603307981632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 22,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sarepta Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000873303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-14895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">93-0797222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">215 First Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-4000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SRPT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>srpt-20230622_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="srpt-20230622.xsd" xlink:type="simple"/>
    <context id="C_429bdaee-dff8-43d5-a577-a638882dff37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_4dbbefb2-f8ef-4307-90b2-ec771fd7645c">0000873303</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_6a49b71e-b558-431a-b87f-853cab1f495b">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_e8d7bd87-fd66-4544-9fa7-04a4e249a9e5">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_b0c2c589-f5bc-4254-b355-76250900c9d3">2023-06-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_fde24faf-9d45-4dab-a1a5-200f99e026e1">Sarepta Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_099970a2-9f04-4156-8107-643658091716">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_2e1dd7bf-5fba-4aa7-b944-48f1f7aeea01">001-14895</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_ff0f1906-fb4f-4d54-85af-e0a817649a6c">93-0797222</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_79e063fa-abcd-4efe-900d-c3a5c3d82391">215 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_84c6b6de-054b-4d6d-b0fa-30f13206ac83">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_f7965db1-ec66-4709-a25b-5669ac9e7745">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_eaa93eb6-3670-4512-b412-71c527eaf3da">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_f7542612-a453-4dd2-ba90-667321b4e6df">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_9012b0c5-2e64-4f73-8127-e2c175ae99ed">274-4000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_44335470-b4cd-4f90-9c36-3521605c8d4f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_4580c544-7a2e-4292-8a62-005db3c62943">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_39e27626-dece-41ed-813a-c266e96a7c44">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_18165d19-5768-4a87-b9d5-f1998d3916a6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_8addc01f-e281-487a-aa99-10965b717b7b">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_6b14555e-291d-4bd7-afca-26a552180715">SRPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_9a23eab1-c5b7-4625-bea2-3f1d9f72c57f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_429bdaee-dff8-43d5-a577-a638882dff37"
      id="F_4fe20c0a-141f-4c8a-bd18-ff47e813a508">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MT&U6<'5]:7(1P<C#PC6@G\ ;__!=>![\2/!U*KX.I5XG</&20Q,<'3XX_4Q
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MD;#N#2%M[F_AJBJ<:?4DLZ@YB[3FW81"J]M%2+O\6[29,A9][P^9'U\:M&+
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #<<M96.JJBYT !   \ @  #P
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M<F]P<R]A<' N>&UL4$L! A0#%     @ W'+65@^U1-#N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ W'+6
M5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #<<M96ZQUE;V$$  "E$   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ W'+6
M5I^@&_"Q @  X@P   T              ( !I P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #<<M96EXJ[',     3 @  "P              @ & #P
M7W)E;',O+G)E;'-02P$"% ,4    " #<<M96.JJBYT !   \ @  #P
M        @ %I$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ W'+65B0>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ W'+65F60>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="srpt-20230622.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="srpt-20230622.htm">srpt-20230622.htm</File>
    <File>srpt-20230622.xsd</File>
    <File>srpt-20230622_lab.xml</File>
    <File>srpt-20230622_pre.xml</File>
    <File>srpt-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "srpt-20230622.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "srpt-20230622.htm"
     ]
    },
    "labelLink": {
     "local": [
      "srpt-20230622_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "srpt-20230622_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "srpt-20230622.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "srpt",
   "nsuri": "http://www.sarepta.com/20230622",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "srpt-20230622.htm",
      "contextRef": "C_429bdaee-dff8-43d5-a577-a638882dff37",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "srpt-20230622.htm",
      "contextRef": "C_429bdaee-dff8-43d5-a577-a638882dff37",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.sarepta.com/20230622/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-23-029354-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-029354-xbrl.zip
M4$L#!!0    ( -QRUE;QD(4*JA0  ,3P   1    <W)P="TR,#(S,#8R,BYH
M=&WM/6M7XSB6W^=7:.C=/G 6)7X_ E5S:!XU=%=!'4+O].Z7/K(E$TTY=MJ6
M(=E?OU>R'1((!50"Q,%5IPILRWK<E^Y3WO_'>!BC:Y;E/$T^;.D=;0NQ)$PI
M3ZX^;!WT#T]/M_[Q<?_O&*.CD],S=,9NT$$H^#4[XGD8IWF1,;3=_[*#3I.8
M)PS]\<O%9W24AL60)0)A-!!BU.MV;VYN.C3B29[&A8"A\DZ8#KL(X[+OPXP1
M>1L=$<%0S] ,$VL.-HQ+W>KI?L_0.[9AVO^E:3U-NWTK'4TR?C40:#O<0?(E
M&#E)6!Q/T E/2!)R$J-^/>0NS#'LH(,X1A?RK1Q=L)QEUXQV9)=_VQ\(@ 7
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MHXAE+6>LB#, Q#B<@?&C>X9N46QL!SM/XY.R[?OF%-W3'9OJ/K9=!ZB>>/(
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M<#TU1F.U[>"X4.LIX(N67Y)%H!4!V0&G&9&"- &=)A2HAJ/;>5*XK(%'J,&
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M%K6[UZBD#>5_,VA>%OE?:!6.9\8J(61A.72-E4;;"@-Y3K7)OG:P:[W?X(L
M!8/I5F/I&W3X8C#]C^WX5;?5W=]O];J[W_S$-R)0"5)F,*-L;!07W?;AX6'[
MH'?0WCTX[-4[7:=VH-P4?MK;;>WU6MW=7NT2[-\LU ^$(N,R,AL"]WI@<;]:
MB#&7,KY@?*ZIZ2!S70P";LCN#"6HDJBJH?&;IR'8^@U;>99LI1[01(^AF-C
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M@][^]SYEN=<KDF<KN#"_K'K!_',9SZJ^$*5#KNBHMM#=8:$AX9SKC\\JW5]
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M$WZ^3+@?3J01E3L3E"U,#;!4NFB.A%1D"0C=VM@@4<RHS;FV[0<Q Q:H[ X
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M7OH)R"42S*/!/'!G/=$ZX<QT[JJ81(*79EK&@1S5DTVU;Q)R#\\KEOL-THO
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MV10  '-R<'0M,C R,S V,C(N>'-D4$L! A0#%     @ W'+65K*9/=NA!0
M!3(  !4              ( !%!@  '-R<'0M,C R,S V,C)?;&%B+GAM;%!+
M 0(4 Q0    ( -QRUE:EZ>;<A 0  .HD   5              "  >@=  !S
M<G!T+3(P,C,P-C(R7W!R92YX;6Q02P$"% ,4    " #<<M96;T%!JL0?   T
M  $ #P              @ &?(@  <W)P="UE>#DY7S$N:'1M4$L%!@     %
-  4 00$  )!"      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
